FRANCES ARNOLD - 26 Feb 2026 Form 3 Insider Report for Generate Biomedicines, Inc. (GENB)

Role
Director
Signature
/s/ Michael Wolf, Attorney-in-Fact
Issuer symbol
GENB
Transactions as of
26 Feb 2026
Net transactions value
$0
Form type
3
Filing time
26 Feb 2026, 20:26:31 UTC
Previous filing
30 Jan 2026
Next filing
04 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ARNOLD FRANCES Director GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE /s/ Michael Wolf, Attorney-in-Fact 26 Feb 2026 0001665419

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GENB Common Stock 232,472 26 Feb 2026 Direct
holding GENB Common Stock 232,472 26 Feb 2026 By The Frances Arnold 2010 Irrevocable Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GENB Stock Option (Right to Buy) 26 Feb 2026 Common Stock 32,916 $6.10 Direct F2
holding GENB Stock Option (Right to Buy) 26 Feb 2026 Common Stock 32,916 $7.25 Direct F3
holding GENB Stock Option (Right to Buy) 26 Feb 2026 Common Stock 32,916 $9.15 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F2 The shares underlying this option vest in sixteen equal quarterly installments following March 1, 2023, subject to the Reporting Person's continued service on each such vesting date.
F3 The shares underlying this option vest in sixteen equal quarterly installments following February 1, 2024, subject to the Reporting Person's continued service on each such vesting date.
F4 The shares underlying this option vest in sixteen equal quarterly installments following February 1, 2025, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney